Archive for April, 2020


In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.

isg_on2

This seminar will look at:

• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future

Agenda:

10.30 – Registration

11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds

11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI

11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics

12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO

12.20 – Q&A with the speakers

12.45 – Networking Lunch

13.45 – Introduction from the Chair
Philip Oliver

13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK

14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences

14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine

14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S

15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne
(then, Williams), In Silico Genesis

15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus

15.30 – Networking drinks

16.30 – Close

Shown above can be found at http://onenucleus.com/onenucleus-events?id=692.

In Silico Genesis signed up a Confidential Disclosure Agreement with ISIS Innovation, the commercial arm of the University of Oxford, and the University of Oxford and plus Baroness Professor Susan Greenfield of Pharmacology of the University of Oxford in June 2013. This 4 way CDA was put in place, following an initial collaborative work with Prof. Greenfield’s lab on a repurposed drug for Alzheimer’s Disease.

In Silico Genesis signed up a Confidential Disclosure Agreement with Public Health England (PHE), previously Health Protection Agency, in June 2013. This CDA was reaffirming an initial CDA placed in October, 2011 between Health Protection Agency (HPA) and In Silico Genesis (ISG) about the antiviral work in collaboration. 

Public Health England (PHE) https://www.gov.uk/government/organisations/public-health-england